Private biotech funding ticks up as venture firms deploy cash
BioPharma
Stay updated with breaking news from Scion Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The venture capital fund will finance companies in Europe who are in the early stages of development with the goal of advancing them to regulatory approval and commercialization.
The facility in Bloomington, Indiana, belonged to contract drugmaker Catalent. FDA inspectors found issues including a "pest" on the manufacturing line. Novo is buying Catalent to boost Wegovy production. Also: A report says FDA oversight of foreign firms making U.S. market drugs is weak.
Though the results were a landslide, the comments demonstrate how polarizing Altman can be, according to Semaphore's 16th annual confidence survey.